Publications by authors named "Mathias Due Buron"

Claim this Profile
S
Socioeconomic impact of initial high vs. moderate efficacy disease-modifying therapy in multiple sclerosis: Effects on labor market affiliation.
Rolf Pringler Holm, Elisabeth Framke, Luigi Pontieri, Malthe Faurschou Wandall-Holm, Mathias Due Buron

Mult Scler Relat Disord· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Maria Dons, Mathias Due Buron, Julie Maria Hejgaard Laursen, Jakob Boesgaard Norsk, Finn Michael Karlsen

Ugeskr Laeger· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up.
Mathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, Hanna Joensen, Matthias Kant

Mult Scler Relat Disord· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis.
Spyridon Kontaxis, Estela Laporta, Esther Garcia, Matteo Martinis, Letizia Leocani, Mathias Due Buron

Sensors (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis.
Spyridon Kontaxis, Estela Laporta, Esther Garcia, Ana Isabel Guerrero, Ana Zabalza, Mathias Due Buron

Front Physiol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis.
Sara Siddi, Iago Giné-Vázquez, Raquel Bailon, Faith Matcham, Femke Lamers, Mathias Due Buron

J Clin Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis.
Malthe Faurschou Wandall-Holm, Mathias Due Buron, Tine Iskov Kopp, Karsten Thielen, Finn Sellebjerg

J Neurol Neurosurg Psychiatry· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks.
Malthe Faurschou Wandall-Holm, Mads Albrecht Andersen, Mathias Due Buron, Melinda Magyari

Front Neurol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-onset MS is associated with an increased rate of reaching disability milestones.
Mads Albrecht Andersen, Mathias Due Buron, Melinda Magyari

J Neurol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
Mathias Due Buron, Tomas Kalincik, Finn Sellebjerg, Per Soelberg Sørensen, Melinda Magyari

J Neurol Neurosurg Psychiatry· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Ismael Barzinji, Bech Danny

Neurology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β.
Mathias Due Buron, Melinda Magyari, Thor Ameri Chalmer, Per Soelberg Sørensen, Finn Sellebjerg

Mult Scler Relat Disord· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Jette Frederiksen, Monika Katarzyna Góra

Neurology· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis